Evidence map›Paper›PMID 17612398›Full record

ArticleBMC developmental biology2007

KIT is required for hepatic function during mouse post-natal development.

Laetitia Magnol, Marie-Clémence Chevallier, Valérie Nalesso, Stéphanie Retif, Helmut Fuchs, Martina Klempt, Patricia Pereira, Michel Riottot, Sandra Andrzejewski, Bich-Thuy Doan and 5 more

Open access · hybridAbstract read
In one paragraph

Article in BMC developmental biology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. c-Kit suppresses atherosclerosis in hyperlipidemic mice.American journal of physiology. Heart and circulatory physiology · 2019
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Laetitia MagnolInstitut de Transgénose, TAAM, UPS44, IEM UMR6218, CNRS, Université Orléans, Orléans, France. magnol@cnrs-orleans.fr <magnol@cnrs-orleans.fr>
Marie-Clémence Chevallier
Valérie Nalesso
Stéphanie Retif
Helmut Fuchs
Martina Klempt
Patricia Pereira
Michel Riottot
Sandra Andrzejewski
Bich-Thuy Doan
Jean-Jacques Panthier
Anne Puech
Jean-Claude Beloeil
Martin Hrabe de Angelis
Yann Hérault
Centre National de la Recherche Scientifique · FRCentre National de Recherche en Génomique Humaine · FRInstitut National de la Recherche Agronomique · MAUniversité d'Orléans · FRUniversité Paris-Sud · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Kit gene encodes a receptor tyrosine kinase involved in various biological processes including melanogenesis, hematopoiesis and gametogenesis in mice and human. A large number of Kit mutants has been described so far showing the pleiotropic phenotypes associated with partial loss-of-function of the gene. Hypomorphic mutations can induce a light coat color phenotype while complete lack of KIT function interferes with embryogenesis. Interestingly several intermediate hypomorphic mutations induced in addition growth retardation and post-natal mortality.

resultsIn this report we investigated the post-natal role of Kit by using a panel of chemically-induced hypomorphic mutations recently isolated in the mouse. We found that, in addition to the classical phenotypes, mutations of Kit induced juvenile steatosis, associated with the downregulation of the three genes, VldlR, Lpin1 and Lpl, controlling lipid metabolism in the post-natal liver. Hence, Kit loss-of-functions mimicked the inactivation of genes controlling the hepatic metabolism of triglycerides, the major source of energy from maternal milk, leading to growth and viability defects during neonatal development.

conclusionThis is a first report involving KIT in the control of lipid metabolism in neonates and opening new perspectives for understanding juvenile steatosis. Moreover, it reinforces the role of Kit during development of the liver and underscores the caution that should be exerted in using KIT inhibitors during anti-cancer treatment.

Indexed as

Gene Expression Regulation, DevelopmentalAllelesAnemiaAnimalsAnimals, NewbornFatty LiverFetal Stem CellsLipid MetabolismLiverMiceMice, Inbred C3HMice, Inbred C57BLMutationPhenotypeProto-Oncogene Proteins c-kitReverse Transcriptase Polymerase Chain ReactionProto-Oncogene Proteins c-kit

Identifiers

PMID17612398
PMCPMC1940254
OpenAlexW2067635268

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.